New sleeping pill may treat Alzheimer's

Share this article:

A new insomnia drug may be used for Alzheimer's and depression, according to its Japanese maker.

Takeda Pharmaceutical Co. Ltd., the Osaka-based drug manufacturer, could extend the use of Ramelteon -- a new sleeping pill to be released in the U.S. market in early fall -- to treat Alzheimer's disease and other illnesses. The new drug, which is in clinical trials in Japan and Europe, has a new mechanism that specifically targets the MT1 and MT2 receptors in the brain, which are critical in regulating the body's sleep-wake cycle.

The company filed for FDA approval for the drug last year and expects to gain approval with "non-scheduled drug" status, which means that no restrictions will be placed on how physicians prescribe the drug. It may start clinical development of the drug to treat Alzheimer's disease and depression after the pill's launch, the company announced.

Share this article:

More in News

Rape investigation blocked by nursing home's HIPAA concerns, authorities say ...

Florida authorities say a nursing home is citing privacy laws to impede the investigation of a possible resident rape, according to local news reports.

Jury hands down $14 million negligent care verdict to 'send message' to nursing homes

Jury hands down $14 million negligent care verdict ...

A Massachusetts jury has awarded $14 million to the family of a nursing home resident who died due to a pressure ulcer, dehydration and other conditions linked to negligent care, ...

CCRC executive director salaries hold steady, therapy directors get boost

Continuing care retirement community executive director salaries have barely increased in the past year, while therapy and rehabilitation directors received a boost, a new report shows. The average salary for a therapy and rehab director is currently $95,905.